Novo Nordisk supports transparency and is committed to compliance with disclosing our financial relationships related to our collaborations with the medical community as required by our industry guideline, namely the ABPI Code of Practice. We believe transparency of financial relationships between those with whom we collaborate is very important to maintaining trust-based relationships with our patients and the public.

Novo Nordisk works alongside Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) to improve the development and delivery of life-enhancing and life-saving medicines for patients.

To ensure that patients have confidence in these relationships, the pharmaceutical industry is taking the lead on disclosing details of payments and other benefits in kind made by Novo Nordisk to HCPs and HCOs.

In-line with current ABPI requirements, Novo Nordisk submits information regarding transfers of the value made to healthcare organisations and healthcare professionals to the ABPI central disclosure platform.  For further information, please visit

In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, Novo Nordisk UK are providing details of the Patient Organisations it partners with, including the nature and financial element of each instance of support. 

Patient Organisation Methodological Note

2023 Transfer of Value provided to UK Patient Organisations

2022 Transfer of Value provided to UK Patient Organisations

2021 Transfer of Value provided to UK Patient Organisations


Collaborative Working refers to pharmaceutical companies working with other organisations to deliver initiatives which either enhance patient care or are for the benefit of patients or alternatively benefit the National Health Service (NHS) and, as a minimum, maintain patient care. 

Please find below details of Novo Nordisk's Collaborative Working Projects. For queries on any of the projects listed, please contact:

Completed projects

Novo Nordisk is committed to transparency in our clinical research and continues to comply with the laws and regulations related to the registration and disclosure of Novo Nordisk sponsored clinical study information.

Summary results from completed Novo Nordisk clinical trials are available via  and

In line with Gender Pay Gap Reporting (GPGR) regulations, all UK companies with more than 250 employees are required to publish their GPGR statistics using data as of 5th April 2022. The metrics cover the gap in pay, the gap in bonus payments, as well as the proportion of genders represented at different pay quartiles, and receiving bonus pay-outs over the previous 12 months period (6 April 2021 to 5 April 2022).

At Novo Nordisk Limited, we are committed to equality, diversity and inclusion across our workforce. We have a number of activities focused on ensuring that employees are paid equally for work of the same value irrespective of gender, and we do not tolerate discrimination on gender or any other protected grounds.

Download our 2022 report